Mineralys therapeutics inc
MLYS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
MLYS 近期報酬表現
7.52%
Mineralys therapeutics inc
6.23%
同產業平均
1.02%
S&P500
與 MLYS 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
XENE | Xenon pharmaceuticals inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
TARA | Protara therapeutics inc | 3 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
SWTX | Springworks therapeutics inc | 2 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
MORF | Morphic holding inc | 3 分 | 2 分 | 2 分 | 3 分 | 1 分 | |
PCVX | Vaxcyte inc | 3 分 | 2 分 | 2 分 | 3 分 | 1 分 |
- XENE Xenon pharmaceuticals inc價值 3 分趨勢 3 分波段 2 分籌碼 3 分股利 1 分查看更多
MLYS 公司資訊
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).